Endeavor BioMedicines, a clinical-stage biotech company, has announced promising phase 2a trial results for its lead investigational candidate, ENV-101.
The recent submission of clinical trial data for Sanofi/Regeneron’s Dupixent and Verona’s Ensifentrine to the U.S. FDA indicates the entry of new therapies for chronic obstructive pulmonary disease (COPD) in 2024.
AN2 Therapeutics recently announced a decision to voluntarily pause enrollment of the phase 3 portion of the phase 2/3 trial, EBO-301, in light of potentially lower than expected efficacy data obtained from the phase 2 trial.
Biotechnology company Vergent Bioscience has revealed that VGT-309, its investigational tumor-targeted fluorescent imaging agent, is able to help surgeons see lung tumors in real time during surgical procedures.
Sanofi is planning to expand the market for its best-selling anti-inflammatory drug Dupixent, used to treat COPD, also known as ‘smokers lung’, after a successful second phase 3 trial.
Arrowhead Pharmaceuticals has spotlighted the potential of RNA interference (RNAi) therapeutic candidates in the lungs, with a clinical late breaker and multiple pre-clinical presentations at this year’s European Respiratory Society (ERS) International...
